CUE vs DAL · rev $9.3M vs P/E 12, rev $61.64B
Cue Biopharma (CUE) versus Delta Air Lines Inc (DAL) — a side-by-side from cached financials, not a winner call.
Cue Biopharma (CUE) is a biotechnology company listed on US.
Delta Air Lines Inc (DAL) is a airlines company listed on US. It is led by Ed Bastian.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
Latest reported DAL revenue for 2024-12-31 was $61.64B. Net income was $3.46B. Revenue was up 6.2% from 2023-12-31 to 2024-12-31. DAL currently screens at market cap $52.18B and trailing P/E 11.6.
CUE currently screens at market cap $59.5M. DAL currently screens at market cap $52.18B and trailing P/E 11.6.
Not investment advice. Open the CUE and DAL stock pages for the full models.
Not investment advice.